YM-430

• Description :

  YM-430 is an oral active calcium entry-blocking and beta-adrenoceptor-blocking agent. YM-430 inhibits Amifampridine (HY-14946) -induced rhythmic contractions with an IC50 value of 59.2 nM and inhibits arginine vasopressin-induced ST-segment depression with an IC50 value of 36.6 mg/kg. YM-430 can be used for study of angina pectoris[1].

• UNSPSC :

  12352005

• Target :

  Adrenergic Receptor; Calcium Channel

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/ym-430.html

• Smiles :

  O=C(C1=C(C)NC(C)=C(C(OC)=O)[C@@H]1C2=CC=CC([N+]([O-])=O)=C2)OCCCCNC[C@H](O)COC3=CC=CC=C3

• Molecular Formula :

  C29H35N3O8

• Molecular Weight :

  553.60

• References & Citations :

  [1]Shibasaki K, et al. Antianginal effects of YM430, a novel calcium entry-blocking and beta-adrenoceptor-blocking agent in several experimental angina models. Gen Pharmacol. 1997;29 (4) :545-550.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [153192-22-4]